Icagen Slashes Trial Enrollment

Icagen Inc. (ICGN) slashed the enrollment in a key study of its sickle cell anemia treatment ICA-17043 by nearly one-half sending shares of the biopharmaceutical plummeting $3.13 to $1.11.